Image Image Image Image Image Image Image Image Image Image
Доступ
Идти наверх

Идти наверх

Oral Omega 3 GA. A phase II in subjects with geographic atrophy secondary to AMD
26/03/2013

Foto49_3

 

Description

A phase II, randomized, double masked clinical trial to establish the safety and efficacy of high oral doses of Omega-3 in patients with geographic atrophy secondary to dry age-related macular degeneration.

Key inclusion criteria

Patients with geographic atrophy secondary to dry age-related macular degeneration.

 

Objectives

The objectives of this study are to evaluate the safety and efficacy of High-Dose Oral Omega 3 on the Photoreceptors/Retinal Pigment Epithelium/Bruch’s membrane complex in subjects with geographic atrophy secondary to age-related macular degeneration and to evaluate whether improvement in visual function occurs and progression to advanced stages of AMD is delayed.

DrMarch_2red

If you are interested in taking part in a clinical trial, please fill in this form to contact us or call +34 935 950 155

Our team of professionals will answer you as soon as possible and we will assess whether you are eligible. 

 

Интравитреальные инъекцииВМД атрофическая или сухая.Экссудативная или влажная ВМДРетинографияАвтофлюоресценцияМикропериметрияФлюоресцентная ангиографияТомография оптической когерентности

Author

Доктор Jordi Monés, M.D., Ph.D.
Номер лицензии COMB: 22.838
Директор
Доктор Медицины и Хирургии
Специалист по Офтальмологии
Специалист по лечению Сетчатки, Макулы и Стекловидного тела

Last modified: 14 November, 2019 - 16:33